XML 40 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900
Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)
1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jul. 15, 2014
Oct. 29, 2014
Feb. 15, 2011
Nov. 30, 2014
Feb. 28, 2016
Mar. 01, 2015
May. 31, 2015
Nov. 29, 2015
Jul. 25, 2013
Customer Relationships [Member] | Minimum [Member]                  
Finite-Lived Intangible Asset, Useful Life         12 years        
Customer Relationships [Member] | Maximum [Member]                  
Finite-Lived Intangible Asset, Useful Life         13 years        
Apio [Member] | Windset [Member] | Senior B Preferred Stock [Member]                  
Investment In Non Public Company Shares   70,000 150,000            
Payments to Acquire Investments $ 11,000,000 $ 7,000,000 $ 15,000,000            
Apio [Member] | Windset [Member] | Junior Preferred Shares [Member]                  
Investment In Non Public Company Shares 51,211                
Apio [Member] | Windset [Member] | Common Stock [Member]                  
Investment In Non Public Company Shares 68   201            
Payments to Acquire Investments     $ 201            
Apio [Member] | Windset [Member]                  
Payments to Acquire Investments $ 11,000,000                
Investment Ownership Percentage               60.00%  
Windset [Member]                  
Investment Ownership Percentage 26.90%       26.90%        
Investments, Fair Value Disclosure         $ 62,500,000   $ 61,500,000    
Bonus Under Long-term Incentive Plan [Member] | Landec Long-Term Incentive Plan [Member]                  
Employee-related Liabilities                 $ 2,000,000
Decrease in Selling, General and Administrative Expenses       $ 677,000          
Landec Long-Term Incentive Plan [Member]                  
Long-term Incentive Plan, Term       3 years          
Sales Revenue, Goods, Net [Member] | Product Concentration Risk [Member] | Ophthalmic [Member] | HA Based Biomaterials [Member]                  
Concentration Risk, Percentage             60.00%    
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Orthopedic [Member] | HA Based Biomaterials [Member]                  
Concentration Risk, Percentage             20.00%    
Number of Proprietary Platforms               2  
Payments to Acquire Investments         $ 18,000,000